Accordingly, Kahlig et al. tested the hypothesis that ranolazine was able to suppress increased persistent current evoked by NaV1.1 mutant channels as a therapeutic strategy for SCN1A-associated epilepsy and migraine syndromes [16]. The gene discussed is SCN1A; the disease is epilepsy.